We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Genentech 证明了 satralizumab 在一种罕见自身免疫性疾病中的疗效。发作风险降低 68%，新病灶减少 79%。了解首个靶向药物如何填补经验性治疗的空白。
